Skip to content
Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy

Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy

Get the podcast

SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German

The Audio Journal of Oncology

SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German Breast Group presented at the 2012 San Antonio Breast Cancer Symposium. ProfessorSibylle Loiblfrom Frankfurt University told Peter Goodwin about findings from their analysis of eight German neoadjuvant studies.

LISTEN

Next in SABCS 2012

All 3 interviews

Interview 2 of 3

Local or regional breast cancer recurrences mandate adjuvant chemotherapy

Local or regional breast cancer recurrences mandate adjuvant chemotherapy

SAN ANTONIO, TEXAS—Patients with local or regional recurrences of breast cancer, should be treated with chemotherapy as well as surgery and

11 December 2012

Related Episodes

Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial

Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial

Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard

6 Mar 2026
12 min
Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy

Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy

Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to node-negative after neoadjuvant chemotherapy do not require axillary lymph node dissection. Less invasive surgical staging procedures were found to be non-inferior in terms of three-year outcomes, irrespective of tumor type or initial stage.

19 Feb 2026
10 min
Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial

Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial

This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.

10 Feb 2026
8 min